Beam Therapeutics/$BEAM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
- Ticker
- $BEAM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 540
- Headquarters
- Cambridge, United States
- Website
- beamtx.com
BEAM Metrics
BasicAdvanced
$2.5B
-
-$0.84
2.23
-
Price and volume
Market cap
$2.5B
Beta
2.23
52-week high
$38.26
52-week low
$20.23
Average daily volume
2M
Financial strength
Current ratio
14.572
Quick ratio
14.254
Long term debt to equity
0.217
Total debt to equity
0.232
Profitability
EBITDA (TTM)
-355.781
Gross margin (TTM)
-161.91%
Net profit margin (TTM)
-55.45%
Operating margin (TTM)
-242.27%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-17.01%
Return on equity (TTM)
-8.18%
Valuation
Price to revenue (TTM)
16.371
Price to book
2.31
Price to tangible book (TTM)
2.31
Price to free cash flow (TTM)
-6.853
Free cash flow yield (TTM)
-14.59%
Free cash flow per share (TTM)
-3.609
Growth
Revenue change (TTM)
158.88%
Earnings per share change (TTM)
-81.28%
3-year revenue growth (CAGR)
24.86%
3-year earnings per share growth (CAGR)
-42.97%
What the Analysts think about BEAM
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
Analyst projections of the future price of Beam Therapeutics stock.
Bulls say / Bears say
In Beam’s small Phase 1/2 readout, a single 60 mg dose raised functional AAT above the protective threshold for up to 18 months; corrected AAT made up 93% of circulating AAT and mutant Z-AAT fell by 84%. These are encouraging signs that BEAM-302 could address the cause of AATD. (GlobeNewswire)
Beam completed dosing in its BEACON sickle cell trial and expects to submit a biologics licence application for risto-cel as early as year-end 2026. That creates a near-term regulatory catalyst for its most advanced programme. (GlobeNewswire)
Beam reported $1.2 billion in cash and marketable securities and expects its cash, together with planned credit-facility draws, to fund operations into mid-2029. This runway gives it time to advance several programmes before it may need further capital. (GlobeNewswire)
BEAM-302’s safety data include a transient Grade 3 liver-enzyme rise in one patient with liver disease at the selected 60 mg dose; mild-to-moderate infusion reactions were also reported in 41% of patients. Larger trials are needed to clarify the risks. (Yahoo Finance)
The BEAM-302 results so far come from a small, open-label study and show changes in biomarkers, not yet slower lung decline or less liver damage. The accelerated-approval approach would still require a confirmatory study to verify clinical benefit. (Yahoo Finance)
Serapha Bio is developing SERP-01 for the same AATD mutation as BEAM-302, backed by $230 million and with a Phase 2/3 start targeted for late 2026 or early 2027. A well-funded rival could narrow Beam’s first-mover advantage. (BioPharma Dive)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
BEAM Financial Performance
Revenues and expenses
BEAM Earnings Performance
Company profitability
Upcoming events
No upcoming events
BEAM News
AllArticlesVideos
Funds containing BEAM
AllUSDGBPEUR
Fund name | Fund size | $BEAM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.17% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.